EPAS1 and metabolic dysfunction-associated steatotic liver disease: Along these lines, a very interesting study has provided consistent and mechanistic evidence that HIF2α involvement in obese and type 2 diabetes patients (i.e., the typical patients that develop progressive NAFLD) is much more complex [137].